Find, compare & contact
Perfluorohexyloctane
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Perfluorohexyloctane API 133331-77-8?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Perfluorohexyloctane. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Perfluorohexyloctane
- Synonyms:
- 1-(perfluorohexyl)octane , F6H8 , NOV03 , Tetradecane, 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluoro-
- Cas Number:
- 133331-77-8
- DrugBank number:
- DB17823
- Unique Ingredient Identifier:
- 7VYX4ELWQM
General Description:
Perfluorohexyloctane, identified by CAS number 133331-77-8, is a notable compound with significant therapeutic applications. Perfluorohexyloctane is a semifluorinated alkane that contains six perfluorinated carbon atoms and eight hydrogenated carbon atoms. It is an inert, slightly amphiphilic compound. Because it is a completely non-aqueous liquid, microbial growth is not possible; therefore, its drug products do not need to be combined with any preservative. Perfluorohexyloctane has been used in the field of ophthalmology as a vitreous substitute. It was approved by the FDA on May 18, 2023 for the treatment of dry eye disease.
Indications:
This drug is primarily indicated for: Perfluorohexyloctane ophthalmic formulation is indicated for the treatment of the signs and symptoms of dry eye disease. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Metabolism:
Perfluorohexyloctane undergoes metabolic processing primarily in: Perfluorohexyloctane was not metabolized by human liver microsomes _in vitro_. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.
Absorption:
The absorption characteristics of Perfluorohexyloctane are crucial for its therapeutic efficacy: Perfluorohexyloctane penetrates meibomian glands, where it has been reported to interact with and dissolve the altered, viscous meibum in the glands. A single pharmacokinetic study showed low systemic perfluorohexyloctane blood levels after topical ocular administration. In rabbits, perfluorohexyloctane was detected in tears at six hours and in meibomian glands at 24 hours following ophthalmic administration, with minimal systemic exposure. The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Pharmacodynamics:
Perfluorohexyloctane exerts its therapeutic effects through: Perfluorohexyloctane is administered ophthalmically to alleviate symptoms of dry eye disease, increase tear film breakup time, and increase lipid layer thickness. Having low surface and interface tensions, perfluorohexyloctane spreads rapidly across the ocular surface. It is reported to cause minimal visual disturbances, attributed to its refractive index being similar to that of water. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Perfluorohexyloctane functions by: Perfluorohexyloctane mediates its actions in the lipid layer and meibomian glands. While the exact mechanism of action is not fully understood, perfluorohexyloctane is believed to interact with the air-liquid interface of the tear film and form a monolayer, preventing the evaporation of the aqueous phase of the tears. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Toxicity:
Categories:
Perfluorohexyloctane is categorized under the following therapeutic classes: Hydrocarbons, Fluorinated, Hydrocarbons, Halogenated, Ophthalmic Solutions, Ophthalmics, Ophthalmological and Otological Preparations, Ophthalmologicals. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Experimental Properties:
Further physical and chemical characteristics of Perfluorohexyloctane include:
- Melting Point: 5
Perfluorohexyloctane is a type of Ophthalmic Agents
Ophthalmic agents belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category specifically designed for ophthalmic applications. These agents are formulated to treat various eye conditions and disorders. Ophthalmic agents encompass a wide range of medications, including eye drops, ointments, gels, and intraocular implants.
These agents are developed to address specific therapeutic needs related to the eyes, such as reducing intraocular pressure in glaucoma, treating inflammation and infection, relieving dryness and itching, and managing allergies. They may also be used to dilate the pupils during diagnostic procedures or surgeries.
Ophthalmic agents are formulated with precise concentrations of active ingredients to ensure efficacy and safety. Common classes of ophthalmic agents include beta-blockers, prostaglandin analogs, carbonic anhydrase inhibitors, corticosteroids, and antihistamines.
When administering ophthalmic agents, it is crucial to follow proper application techniques to ensure optimal drug delivery and minimize side effects. Eye drops, for example, are typically applied as a gentle instillation into the conjunctival sac, while ointments are applied along the lower eyelid.
These pharmaceutical API ophthalmic agents undergo rigorous quality control and regulatory scrutiny to meet industry standards and ensure patient safety. Manufacturers must comply with Good Manufacturing Practices (GMP) and adhere to stringent quality assurance protocols.
Overall, ophthalmic agents play a vital role in the management and treatment of various eye conditions, providing patients with targeted relief and improving ocular health. It is important to consult with a healthcare professional to determine the appropriate ophthalmic agent for individual needs and to receive proper guidance on usage and potential side effects.
